

# Relationship of CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> Score to Left Atrial Remodeling Detected by Velocity Vector Imaging in Patients with Atrial Fibrillation

Yihui Li<sup>1,2</sup>, Wenyuan Ding<sup>1,2</sup>, Hua Wang<sup>1,2</sup>, Nianpeng Song<sup>1,2</sup>, Leyu Lin<sup>1,2</sup>, Zhihao Wang<sup>1,2</sup>, Ming Zhong<sup>1,2</sup>, Yun Zhang<sup>1,2</sup>, Wei Zhang<sup>1,2\*</sup>

**1** Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Jinan, P.R. China, **2** Qilu Hospital of Shandong University, Jinan, P.R. China

## Abstract

**Background:** The CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc scores are used to predict thrombo-embolic/stroke in patients with nonvalvular atrial fibrillation (AF). Nevertheless, limited data are available regarding the association between these risk stratification for stroke and left atrial (LA) remodeling status of AF patients. The purpose of this study was to explore the association between these scores and LA remodeling status assessed quantitatively by echocardiography in AF patients.

**Methods:** One hundred AF patients were divided into 3 groups based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc/CHADS<sub>2</sub> score: the score of 0 (low stroke risk), the score of 1 (moderate stroke risk) and the score of  $\geq 2$  (high stroke risk). All patients were performed through conventional and velocity vector imaging echocardiography. Echocardiographic parameters: maximum LA volume index (LAVImax), LA total emptying fraction (LAEFt) and LA mean strain were obtained to assess quantitatively LA remodeling status.

**Results:** On categorizing with CHA<sub>2</sub>DS<sub>2</sub>-VASc, the score of 1 group showed augment in LAVImax and attenuation in LA mean strain derived from VVI, compared with the score of 0 group (LAVImax: 40.27 $\pm$ 21.91 vs. 26.79 $\pm$ 7.87,  $p=0.002$ ; LA mean strain: 15.18 $\pm$ 6.36 vs. 22 $\pm$ 8.54,  $p=0.001$ ). On categorizing with the CHADS<sub>2</sub> score, similar trends were seen between the score of  $\geq 2$  and 1 groups (LAVImax: 43.72 $\pm$ 13.77 vs. 31.41 $\pm$ 9.50,  $p<0.001$ ; LA mean strain: 11.01 $\pm$ 5.31 vs. 18.63 $\pm$ 7.00,  $p<0.001$ ). With multivariate logistic regression, LAVImax (odds ratio: 0.92, 95% CI: 0.85 to 0.98,  $p=0.01$ ) and LA mean strain reflecting LA remodeling (odds ratio: 1.10, 95% CI: 1.02 to 1.19,  $p=0.01$ ) were strongly predictive of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0.

**Conclusions:** The superiority of the CHADS<sub>2</sub> score may lay in identifying LA remodeling of AF patients with high stroke risk. Whereas, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score was better than the CHADS<sub>2</sub> score at identifying LA remodeling of AF patients presenting low stroke risk.

**Citation:** Li Y, Ding W, Wang H, Song N, Lin L, et al. (2013) Relationship of CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> Score to Left Atrial Remodeling Detected by Velocity Vector Imaging in Patients with Atrial Fibrillation. PLoS ONE 8(10): e77653. doi:10.1371/journal.pone.0077653

**Editor:** Xiongwen Chen, Temple University, United States of America

**Received:** May 21, 2013; **Accepted:** September 12, 2013; **Published:** October 17, 2013

**Copyright:** © 2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the research grants from Key Technologies R & D Program of Shandong Province (2010G0020262), the Independent Innovation Foundation of Shandong University (2012JC034), the Natural Science Foundation of Shandong Province (ZR2009CM022, ZR2009CM025, Y2008C47), the National Natural Science Foundation of China (30971215, 81070192, 81070141, 81100605, 81270352 and 81270287), the National Basic Research Program of China (973 Program, grant number 2009CB521904). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

\* E-mail: zhangweisduqilu@gmail.com

## Introduction

Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice [1]. The incidence of thrombo-embolic/stroke increases by an average fivefold in the presence of AF [2]. To stratify thrombo-embolic risks in patients with nonvalvular AF and to identify patients eligible for anticoagulation, two stroke risk stratification schemes have been widely applied in clinical

practice, including the CHADS<sub>2</sub> score (Congestive heart failure, Hypertension, Age  $\geq 75$ , Diabetes, Stroke [doubled]) [3] and the CHA<sub>2</sub>DS<sub>2</sub>-VASc score (Congestive heart failure, Hypertension, Age  $\geq 75$  [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74, and Sex category [female]) [4].

Many studies have demonstrated that the risk factors in the two stratification schemes also contribute to triggering a slow but progressive process of LA structural and functional

changes in every AF patients, termed as LA remodeling [5]. Meanwhile, LA remodeling is a critical substrate of thromboembolic tendency in AF [6]. Therefore, the CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc score might represent LA remodeling status, and a higher stroke risk possibly imply a more serious atrial remodeling status. Precise assessment of LA remodeling could improve our ability to predict the risk of developing stroke and the response to treatments in patients with this arrhythmia [7]. However, their precise association is incompletely understood. Compared with pure conventional echocardiograph, the combination of velocity vector imaging (VVI) and conventional echocardiograph could offer more comprehensive echocardiographic parameters quantitatively reflecting status of LA remodeling, such as atrial volume, ejection fraction and strain [7–10].

Our study was undertaken to determine the association of the CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc score and the LA remodeling status quantitatively evaluated by both conventional echocardiograph and VVI in AF. In addition, we also sought to fully assess incremental value over various echocardiographic parameters for predicting the stroke risk.

## Methods

It's a single-center, retrospective, cross-sectional study. The study was approved by the Ethics Committee of Qilu Hospital of Shandong University, Jinan, China. All subjects gave written informed consent to participate in this study. One hundred consecutive patients with nonvalvular AF attending Qilu Hospital in Shandong Province between March 2010 and July 2012 were included in this study. All AF patients underwent routine echocardiographic study after initial treatment in the E.R. or in the cardiology department of the Qilu Hospital. Subjects with valve disease, primary myocardial and pericardial diseases were excluded. To stratify the subjects, comorbid conditions and other risk factors such as congestive heart failure, hypertension, age  $\geq 75$ , diabetes, history of stroke, vascular disease, age 65–74, and sex category were taken into account according to the CHA<sub>2</sub>DS<sub>2</sub>-VASc or CHADS<sub>2</sub> scheme criteria [5,11]. In both CHA<sub>2</sub>DS<sub>2</sub>-VASc or CHADS<sub>2</sub> scheme systems, a score of 0 was categorized into low risk, a score of 1 was moderate risk, and score  $\geq 2$  was high risk [12].

All subjects were examined in the left lateral decubitus using the Siemens Sequoia c512 ultrasound machine, revision 8.0 (Siemens Medical Systems, Mountain View, CA, USA) and a 4 V1c transthoracic transducer during quiet respiration. All echocardiograms were performed by 2 experienced operators (Yihui Li, Nianpeng Song) with no previous specific information about the study objects.

All echocardiographic images were recorded by the Digital Imaging and Communication in Medicine (DICOM) and formatted file images were then exported to a personal computer. All analyses were performed off line with software Syngo US Workplace (Siemens Medical Solutions, Mountain View, CA, USA, revision 3.0).

## Conventional echocardiography

Two-D images were acquired from the apical 4-chamber and 2-chamber views according to standard techniques [13].

All LA volumes were calculated from the apical 4-chamber and 2-chamber views using the biplane method of discs [14]. All LA volumes were indexed to body surface area for LA volumes index (1). Maximum LA volume index (LAVI<sub>max</sub>) was defined as the largest LA volume index, in ventricular systole just before mitral valve opening; (2) minimal LA volume (LAVI<sub>min</sub>) was defined as the smallest LA volume index, after mitral valve closure. The LA emptying parameters were derived from LA volumes index: LA total emptying fraction (LAEF) =  $(LAVI_{max} - LAVI_{min}) / LAVI_{max}$  [15].

Left ventricular systolic and diastolic function: LV ejection fraction (LVEF) was calculated using the biplane Simpson's rule [16]. The left ventricular diastolic function was assessed by E/e'<sub>sep</sub>, the ratio of mitral inflow E velocity to myocardial e'<sub>sep</sub> velocity in the septal mitral annulus [17,18].


## Velocity vector imaging (VVI)

High quality apical 4-chamber and 2-chamber gray scale views images were obtained on the condition of quiet breath and a stable and distinct ECG recording. The endocardium of the LA walls on apical 2-chamber, 4-chamber view was manually traced starting from the medial to the lateral mitral annulus and was tracked by the VVI software along the border throughout 2 to 3 cardiac cycles. Accuracy of border tracking was manually verified and adjusted if needed. The tracing was performed several times to achieve the most accurate endocardial border. Thus, strain versus time curves were generated from these regions of interest (Figure 1). Strain measurements performed in the myocardium of the 8 LA segments (each basal, mid segments of LA septal, lateral, inferior, anterior wall) were calculated by averaging values for LA mean strain. The apical segments' data with pulmonary veins and atrial appendage was excluded as recommended [7,19].

## Statistical Analysis

Continuous data are presented as mean  $\pm$ SD. Categorical data are summarized as frequencies and percentages. One-way ANOVA of normal distributional continuous data was used to compare the differences among groups of subjects. Comparison of the prevalence of comorbid conditions (hypertension, coronary artery disease, heart failure, etc.) were made using the  $\chi^2$  test or Fisher exact tests if necessary. Univariate and multivariate linear regressions were used to determine the variables for predicting LA mean strain [20]. Univariate and multivariate logistic regression analyses in AF to determine the predictors of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0. The receiver-operator characteristic (ROC) curve testing diagnostic value of the various echocardiographic parameters model (in which LVEF and E/e'<sub>sep</sub> reflected the left ventricular function, LAEF, LAVI<sub>max</sub> and LA mean strain reflected the left atrial function) was used to predict the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 in AF group.

Bland-Altman plots were used to assess the reproducibility of intraobserver and interobserver. A performer (Yihui Li)



**Figure 1. Examples of strain wave of curves of different colors representing the strain of different segments of atrial walls.** Imagine A (from 4-chamber view) and B (from 2-chamber view) show the strain wave from a paroxysmal AF subjects.

doi: 10.1371/journal.pone.0077653.g001

repeated VVI and obtained strain data of 10 randomly selected patients at two different time points to determine the intraobserver reproducibility. Another performer (Nianpeng Song) obtained VVI data of the same 10 patients independently for the interobserver reproducibility. The mean bias and limits of agreement (1.96±SD) from Bland-Altman plot are presented for the reproducibility of intraobserver and interobserver. All statistical analyses were performed using SPSS 18.0 software (SPSS Inc., Chicago, Illinois, USA). *p* values <0.05 were considered statistically significant.

## Results

### Study population

Baseline characteristics for the overall study population are presented in Table 1. There was no statistical difference in duration of AF, lab parameters. Compared with the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 score and 1 score group, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥2 group had significantly increased systolic and diastolic blood pressure (*p*<0.01~0.001), persistent AF (*p*<0.05~0.01), stroke events after AF (*p*<0.05~0.01) and angiotensin ii receptor blockers (ARB) drug utilization (*p*<0.01).

### Left ventricular systolic and diastolic function

Conventional left ventricular functional parameters from the study population are presented in Table 2. AF with CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 had lower LVEF and higher E/e' sep significantly (*p*<0.01). There were no significant differences between the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 and CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1 group about left ventricular function.

### Left atrial remodeling status categorized by CHADS<sub>2</sub> score

On categorizing AF patients based on the CHADS<sub>2</sub> score, the difference of LAVImax and LAEFt between 1 score and 0 score group wasn't significant (LAVImax: 31.41±9.50 vs.

33.98±16.70, *p*=0.45; LAEFt: 28.83±9.90 vs. 28.71±9.62, *p*=0.96) (Figure 2.A). Similarly, no significant difference of LA mean strain between the CHADS<sub>2</sub> score of 1 group and 0 group could be shown (18.63±7.00 vs. 18.33±8.57, *p*=0.867) (Figure 3.A).

Whereas LAVImax was increased and LAEFt was reduced significantly in ≥2 score group compared with 1 score group (LAVImax: 43.72±13.77 vs. 31.41±9.50, *p*<0.001; LAEFt: 19.18±8.53 vs. 28.83±9.90, *p*<0.001) (Figure 2.A). And significant decrease in LA mean strain was present in ≥2 score group compared with 1 score group. (11.01±5.31 vs. 18.63±7.00, *p*<0.001) (Figure 3.A).

### Left atrial remodeling status categorized by CHA<sub>2</sub>DS<sub>2</sub>-VASc score

Categorized by CHA<sub>2</sub>DS<sub>2</sub>-VASc, the 1 score group was significantly higher in LAVImax (40.27±21.91 vs. 26.79±7.87, *p*=0.002) compared with 0 score group (Figure 2.B). Likewise, LA mean strain in the 1 score group decreased significantly compared with 0 score group (15.18±6.36% vs. 22±8.54%, *p*=0.001) (Figure 3.B). LAEFt was lower in 1 score group compared with 0 score group (27.51±9.14 vs. 31.08±9.45, *p*=0.19), but the difference didn't reach statistical significance (Figure 2.B).

Nevertheless, there were no significant difference of left atrial echocardiographic values between 1 score and ≥2 score group (LAVImax: 40.27±21.91 vs. 39.80±13.35, *p*=0.916; LAEFt: 27.51±9.14 vs. 22.19±10.05, *p*=0.02; LA mean strain: 15.18±6.36% vs. 13.86±7.10%, *p*=0.46) (Figure 2.B, 3.B).

### The correlation of echocardiographic parameters assessing left atrial remodeling

Univariate and multivariate regression analysis was used to determine the predictors of LA mean strain. The results of the regression analysis are shown in Table 3. Multivariate analysis revealed LA mean strain was correlated with LAVImax and

**Table 1.** Comparison of clinical characteristics in AF with different CHA<sub>2</sub>DS<sub>2</sub>-VASc score.

Clinical characteristics	CHA <sub>2</sub> DS <sub>2</sub> -VASc		
	0 (n = 25)	1 (n = 27)	≥2 (n = 48)
Age>75	0 (0%)	0 (0%)	4 (8.3%)
Age 65–74 y	0 (0%)	6 (22.2%)*	20 (41.7%)*
Congestive heart failure	0 (0%)	1 (3.7%)	19 (39.6%)*
Hypertension	0 (0%)	7 (25.9%)*	28 (58.3%)*
Diabetes	0 (0%)	6 (22.2%)	7 (14.6%)
Stroke	0 (0%)	1 (3.7%)	18 (37.5%)*
Vascular disease	0 (0%)	1 (3.7%)	2 (4.2%)
Female gender	0 (0%)	6 (22.2%)*	25 (52.1%)*
SBP, mmHg	124.8 ± 8.83	130.89 ± 19.69	144.19 ± 16.98***
DBP, mmHg	76.2 ± 7.58	82.26 ± 13.55	84.17 ± 13.73**
Ventricular rate, prm	81.63 ± 16.23	80.48 ± 24.98	80.69 ± 16.65
BMI, kg/m <sup>2</sup>	25.7 ± 2.71	25.25 ± 4.45	26.92 ± 4.11
Waist-Hip Ratio	0.92 ± 0.04	0.89 ± 0.06	0.91 ± 0.06
FBG, mmol/L	5.24 ± 0.59	6.08 ± 2.67	5.57 ± 1.19
TC, mmol/L	1.66 ± 0.84	1.58 ± 1.43	1.56 ± 0.85
TG, mmol/L	4.62 ± 0.72	4.74 ± 1.3	4.72 ± 1.31
HDL, mmol/L	1.16 ± 0.27	1.25 ± 0.34	1.21 ± 0.28
LDL, mmol/L	2.59 ± 0.5	2.62 ± 0.87	2.74 ± 0.99
AF history, month	67.77 ± 69.15	47.44 ± 38.8	71.68 ± 75.71
Persistent AF	8 (32%)	11 (40.7%)	31 (64.6%)*
Stroke events after AF	0 (0%)	1 (3.7%)	13 (27.1%)*
Previous antiarrhythmic drugs	21 (84%)	19 (70.4%)	39 (81.3%)
Previous antiplatelet drugs	11 (44%)	16 (59.3%)	33 (68.8%)
Previous anticoagulation drugs	8 (32%)	9 (33.3%)	18 (37.5%)
CCB	2 (8%)	6 (22.2%)	15 (31.3%)
ACEI	5 (20%)	4 (14.8%)	14 (29.2%)
ARB	2 (8%)	5 (18.5%)	18 (37.5%)**

SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, Body mass index; FBG, Free blood glucose; TG, total triglyceride; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin ii receptor blockers, CCB, calcium channel blocker; \* $p < 0.05$  compared with 0 score group; \*\* $p < 0.01$  compared with 0 score group; \*\*\* $p < 0.001$  compared with 0 score group; † $p < 0.05$  compared with 1 score group; †† $p < 0.01$  compared with 1 score ; ††† $p < 0.001$  compared with 1 score group.

doi: 10.1371/journal.pone.0077653.t001

**Table 2.** Left ventricular systolic and diastolic function of AF with different CHA<sub>2</sub>DS<sub>2</sub>-VASc score.

Left ventricular function	CHA <sub>2</sub> DS <sub>2</sub> -VASc score		
	0 (n=25)	1 (n=27)	≥2 (n=48)
LVEF, %	61 ± 7	58 ± 8	54 ± 1**
E/A	1.12 ± 0.41	1.02 ± 0.33	1.04 ± 0.46
E/e' (SEP)	5.12 ± 2.17	6.01 ± 1.73	6.96 ± 2.41**

LVEF, LV ejection fraction; E/A, the ratio of Early (E) and late (A) wave velocities from Pulsed Doppler mitral inflow; E/e' (sep), the ratio of mitral inflow E velocity to myocardial e' sep velocity in the mitral annulus; \*\* $p < 0.01$  compared with 0 score group.

doi: 10.1371/journal.pone.0077653.t002

LAEft ( $R^2 = 0.559$ ,  $p = 0.03$  and  $p < 0.001$  for LAVImax and LAEft, respectively).

### The value over various echocardiographic parameters for predicting the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0

Logistic regression analysis in AF identified LAVImax (odds ratio: 0.92, 95% CI: 0.85 to 0.98,  $p = 0.01$ ) and LA mean strain (odds ratio: 1.10, 95% CI: 1.02 to 1.19,  $p = 0.01$ ) as the echocardiographic variables that were associated with greater predictive odds of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 (Table 4).


The receiver-operator characteristic (ROC) curve was used to test diagnostic value of various echocardiographic parameters models in predicting AF of CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0. The model A (LVEF + E/e' sep + LAEft + LAVImax + LA mean strain) increased in the area under the receiver-operator characteristic curve (AUC) about 0.03 from the model B (LVEF + E/e' sep + LAEft + LAVImax). Unfortunately, the difference didn't arrive at the statistical significance (the model A: AUC: 0.82, 95%CI: 0.73 to 0.91, the model B: AUC: 0.79, 95%CI: 0.69 to 0.88,  $p = 0.59$ )(Figure 4).

### Intraobserver and interobserver reproducibility


Intraobserver and interobserver reproducibility for LA mean strain derived from VVI are presented in Figure 5. The mean bias of intraobserver was 0.6 (limits of agreement, -3.4 to 4.6) for LA mean strain. The mean bias of interobserver was 0.1 (limits of agreement, -4.2 to 4.4) for LA mean strain (Figure 5).

### Discussion


In this study, we demonstrated the relationship between the LA remodeling and CHADS<sub>2</sub> /CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Both scoring systems may identify LA remodeling status and each has its own merits. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score demonstrated the superiority of distinguishing LA remodeling of AF patients with the low stroke risk from moderate stroke risk. Meanwhile, the CHADS<sub>2</sub> score had its potential in identifying LA remodeling of AF patients with the high stroke risk. Furthermore, echocardiographic parameters reflecting LA remodeling: LAVImax and LA mean strain derived from VVI



**Figure 2. Left atrial volume index and ejection fraction of AF with different stroke risk score.** Low(CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0), moderate (CHADS<sub>2</sub> /CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1), and high (CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥2) risk; Maximum LA volume index; LAEFt , LA total emptying fraction; LAEPf.  
doi: 10.1371/journal.pone.0077653.g002



**Figure 3. Distribution of LA mean strain of AF with different stroke risk score.** Low (CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0), moderate (CHADS<sub>2</sub> /CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 1), and high (CHADS<sub>2</sub>/CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥2) risk; The central box represents the values from the lower to upper quartile (25th to 75th percentile). The middle line represents the median. The whiskers extend from the minimum to the maximum value.  
doi: 10.1371/journal.pone.0077653.g003



**Figure 5. Intraobserver and Interobserver Reproducibility for VVI derived LA Mean strain and LA Mean strain Rate.** The mean bias intraobserver was 0.6 (limits of agreement, -3.4 to 4.6,) for LA mean strain. The mean bias interobserver was 0.1 (limits of agreement, -4.2 to 4.4,) for LA mean strain.  
doi: 10.1371/journal.pone.0077653.g005

showed incremental value in assessing CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0.

AF and concomitant stroke risk factors have caused extensive and severe abnormalities in ultrastructure, including

progressive endocardial denudation, imbalance in collagen synthesis and degradation, and oedematous or fibroelastic infiltration of the extracellular matrix [21]. The ultrastructural changes may enhance atrial dilatation, loss of atrial contractile

**Table 3.** Univariate and multivariate regression analysis for LA mean strain in AF.

Variable	Univariate regression		Multivariate regression			Adjusted R <sup>2</sup>
	Coefficient	p	Coefficient	SE	p	
LAVImax	-0.17	0.13	-0.22	0.06	0.03	0.559
LAEFt	0.47	0.02	0.63	7.77	<0.001	-
LVEF	0.07	0.61	-	-	-	-
E/e`sep	-0.09	0.41	-	-	-	-
Age	-0.08	0.49	-	-	-	-
BMI	0.11	0.33	-	-	-	-
SBP	-0.12	0.36	-	-	-	-
DBP	-0.07	0.64	-	-	-	-
Ventricular rate	-0.03	0.79	-	-	-	-
Type of AF	0.15	0.45	-	-	-	-
History of AF	-0.06	0.55	-	-	-	-
FBG	-0.06	0.55	-	-	-	-

Maximum LA volume index; LAEFt, LA total emptying fraction; LAEFp; LVEF, left ventricular ejection fraction; E/e`sep, the ratio of mitral inflow E velocity to myocardial e`sep velocity in the mitral annulus; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, Body mass index; FBG, Free blood glucose.

doi: 10.1371/journal.pone.0077653.t003

**Table 4.** Univariate and multivariate Logistic Regression Analysis for Prediction CHA<sub>2</sub>DS<sub>2</sub>-VASc score=0.


Variable	Univariate			Multivariate		
	OR	95%CI	p	OR	95%CI	p
LAVImax	0.912	0.85 - 0.98	0.02	0.92	0.85-0.98	0.01
LA mean strain	1.117	1.01 - 1.23	0.03	1.10	1.02-1.19	0.01
LVEF	2.572	0 - 24267.71	0.84	-	-	-
E/e`sep	1.016	0.81 -1.27	0.89	-	-	-
LAEFt	0.100	0 -176.96	0.55	-	-	-

LAVImax, maximum LA volume index; LAEFt, LA total emptying fraction; LAEFp; LVEF, left ventricular ejection fraction; E/e`sep, the ratio of mitral inflow E velocity to myocardial e`sep velocity in the mitral annulus.

doi: 10.1371/journal.pone.0077653.t004

force and decreased atrial wall compliance [22]. These atrial remodeling in AF patients could lead to further echocardiography changes.

Traditional approaches assessing atrial remodeling is conventional echocardiography in clinical practice [8,23]. A widely used parameter of assessing LA remodeling by echocardiography is LA Anterior-Posterior diameter in the parasternal long-axis view [7]. However, previous studies have shown little relationship between left atrial diameter by conventional echocardiography and stroke risk in AF [24]. Our results revealed the incremental relationship among LAVImax, LA mean strain and the CHADS<sub>2</sub> /CHA<sub>2</sub>DS<sub>2</sub>-VASc score. AF patients' predominant enlargement of LA in the superior-inferior and medial-lateral dimensions could alter LA geometry such that the Anterior-Posterior diameter may not be representative



**Figure 4.** Diagnostic value ROC curve of various cic parameters. The receiver-operator characteristic (ROC) curve testing diagnostic value of left ventricular ejection fraction (LVEF), the ratio of mitral inflow E velocity to myocardial e`sep velocity in the mitral annulus(E/e`sep), Maximum LA volume index(LAVImax), LA total emptying fraction(LAEFt), LA mean strain in predicting CHA<sub>2</sub>DS<sub>2</sub>-VASc score=0 in AF. Two models have different patient numbers that might lead to a small difference in area under the receiver-operator characteristic curve (AUC).Model A: AUC: 0.82, 95%CI: 0.73 to 0.91; Model B: AUC: 0.79, 95%CI: 0.69 to 0.88, p =0.59.

doi: 10.1371/journal.pone.0077653.g004

of LA size. There are either good agreement or a tendency for biplane method to underestimate comparative LA volumes [25]. For these reasons, cumulative changes in LA remodeling should be measured by LA volume index in research [26]. LA ejection fraction has been associated with left ventricular systolic and diastolic function [25]. In our study, some AF with CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2 had abnormal left ventricular function. So LAEFt couldn't assess the LA remodeling of AF with left ventricular dysfunction exactly, compared with LA volume index and LA mean strain.

LA strain derived from VVI can reflect dynamic changes that may precede volumetric changes [10]. Because of the combination of speckle tracking (a series of unique B-mode pixel tracking algorithms), mitral annulus motion and tissue-blood border detection, VVI show more feasible and reproducible in assessing LA remodeling status of very thin atrial wall, compared with other echocardiographic methods [7], recently been applied to the evaluation left atrial mechanical dysfunction in coronary artery disease patients [8], regional myocardial dysfunction in patients with acute myocardial infarction [27], have emerged as a quantitative technique for the estimation of myocardial structure and function. Especially, LA strain derived from the VVI is inversely related to LA wall fibrosis, a key hallmark of LA remodeling. Furthermore, the strain wasn't influenced by age, sex, severity of mitral regurgitation. In our study, LA mean strain was correlated with LA functional parameters (LAVImax and LAEFt) rather than ventricular parameters or clinical characteristics (Table 3).

The most common stroke risk factors (like the aging, hypertension, heart failure and so on) are most critical

upstream concomitant conditions promoting atrial remodeling. Upstream therapy for these coexisting comorbidities can delay, even reverse LA remodeling [5,22]. AF patients with stroke risk factors have more severe abnormalities in ultrastructure [21]. Given all that, more stroke risk factors imply more serious left remodeling status, vice versa. In our study, those AF patients with more stroke risk factors or higher stroke scores had more significant enlargement LA, loss of atrial contraction and reduced strain.

It is recommended to use several, rather than single doppler echocardiographic technique for the accurate assessment of atria or concomitants events [28,29]. So our study attempted to combine multiple echocardiographic parameters model to predict the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0. We also examined the diagnostic value of conventional echocardiographic parameters model after adding LA mean strain, the ROC was 0.82. Disappointedly, the difference didn't reach the statistical significance ( $p = 0.59$ ) (Figure 4). So further studies are necessary to investigate the superiority of strain in predicting the CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 and clarify the detailed mechanisms.

North American and European guidelines on atrial fibrillation (AF) are conflicting regarding the classification of patients at low/intermediate risk of stroke [30]. A previous study demonstrated the relationship between LA strain and the stroke risk as quantified with CHADS<sub>2</sub> score [10], its categorization was based on that CHADS<sub>2</sub> score < 2 was low, CHADS<sub>2</sub> score 2 or 3 was moderate, and CHADS<sub>2</sub> score > 3 was high risk. However, according to the guideline of the 2012 edition of the American College of Chest Physicians (ACCP) Guidelines on Antithrombotic Therapy and Prevention of Thrombosis [31] and the 2010 Guidelines for the management of atrial fibrillation of the European Society of Cardiology (ESC) [5], the CHADS<sub>2</sub> score of 0 is as low, CHADS<sub>2</sub> score of 1 is as moderate, and CHADS<sub>2</sub> score of > 2 is as high risk. Regarding of that, our results revealed that AF with CHADS<sub>2</sub> score of  $\geq 2$  (high stroke risk) showed high risk remodeling additionally.

The 2012 focused update of the ESC Guidelines for the management of atrial fibrillation strongly recommends a practice shift towards greater focus on identification of 'truly low-risk' patients with AF. What's more, lots of evidence showed that the CHA<sub>2</sub>DS<sub>2</sub>-VASc was better at identifying 'truly low risk' patients with AF who wouldn't develop stroke and thrombo-embolism and a CHADS<sub>2</sub> score of 0 does not reliably identify AF patients who are 'truly low-risk' [11]. Our study revealed that AF with CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 might have truly low level LA remodeling, but AF with CHADS<sub>2</sub> score of 0 may have similar LA remodeling level with CHADS<sub>2</sub> score of 1, who would subsequently suffer from strokes. Our results could

be one reason why real-world cohort data confirmed that not all of the patients with CHADS<sub>2</sub> score of 0 were low risk, who faced stroke inevitably [12].

### Limitations

The population of our study was relatively small. Variations in drug utilization may have resulted in data variability. ARB can prevent and suppress the promotion of atrial structural and electrical remodeling [32,33]. CHA<sub>2</sub>DS<sub>2</sub>-VASc score of  $\geq 2$  group using more prevalent ARB failed to present better amelioration, so we consider that variations in ARB or other related drugs utilization may not affect atrial remodeling outcomes in our study prominently. Further confirmation is needed in larger, prospective investigations. The bias of echocardiographic parameters in intraobserver and interobserver depends on many factors. Two experienced performers (Yihui Li and Nianpeng Song) obtained and analyzed the echocardiographic data according with standard method. Bland-Altman plot also demonstrated feasible and reproducible results by VVI. The duration from last atrial fibrillation attack may affect the atrial and ventricular function in the paroxysmal AF. Therefore, we performed the echocardiograph to decrease this factor's influence when the paroxysmal AF patients maintained sinus rhythm after treatments.

### Conclusions

The superiority of the CHADS<sub>2</sub> score may lay in identifying LA remodeling of AF patients with high stroke risk. Whereas, the CHA<sub>2</sub>DS<sub>2</sub>-VASc score was better than the CHADS<sub>2</sub> score at identifying LA remodeling of AF patients presenting low stroke risk. The superiority of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score over CHADS<sub>2</sub> in identifying LA remodeling of low stroke risk AF patients may partly account for the fact that the CHA<sub>2</sub>DS<sub>2</sub>-VASc is better at identifying 'truly low stroke risk' AF patients in real-world cohort.

### Acknowledgments

We deeply thank Guihua Jiang for her assistance in performing the experiments for this study.

### Author Contributions

Conceived and designed the experiments: YHL WZ MZ ZHW. Performed the experiments: YHL NPS LYL. Analyzed the data: YHL ZHW. Contributed reagents/materials/analysis tools: WYD HW MZ YZ ZHW WZ. Wrote the manuscript: YHL.

### References

1. Wolf PA, Dawber TR, Thomas HE, Kannel WB (1978) Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The framingham Study. *Neurology* 28: 973–973. doi:10.1212/WNL.28.10.973. PubMed: 570666.
2. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB (1998) Impact of atrial fibrillation on mortality, stroke, and medical costs. *Arch Intern Med* 158: 229–234. doi:10.1001/archinte.158.3.229. PubMed: 9472202.
3. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW et al. (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *J Am Med Assoc* 285: 2864–2870. doi:10.1001/jama.285.22.2864. PubMed: 11401607.
4. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 137: 263–272. doi:10.1378/chest.09-1584. PubMed: 19762550.

5. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 31: 2369–2429. doi:10.1093/eurheartj/ehq278. PubMed: 20802247.
6. Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet* 373: 155–166. doi: 10.1016/S0140-6736(09)60040-4. PubMed: 19135613.
7. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG et al. (2010) Left Atrial Strain and Strain Rate in Patients With Paroxysmal and Persistent Atrial Fibrillation. *Circ Cardiovasc Imaging* 3: 231–239. doi:10.1161/CIRCIMAGING.109.865683. PubMed: 20133512.
8. Tayyareci Y, Yildirimtürk O, Aytekin V, Memic K, Behramoglu F et al. (2010) Preoperative Left Atrial Mechanical Dysfunction Predicts Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Operation. *Circ J* 74: 2109–2117. doi:10.1253/circj.CJ-10-0197. PubMed: 20818132.
9. Leung DY, Boyd A, Ng AA, Chi C, Thomas L (2008) Echocardiographic evaluation of left atrial size and function: current understanding, pathophysiologic correlates, and prognostic implications. *Am Heart J* 156: 1056–1064. doi:10.1016/j.ahj.2008.07.021. PubMed: 19032999.
10. Saha SK, Anderson PL, Caracciolo G, Kiotsekoglou A, Wilansky S et al. (2011) Global Left Atrial Strain Correlates with CHADS<sub>2</sub> Risk Score in Patients with Atrial Fibrillation. *J Am Soc Echocardiogr* 24: 506–512. doi:10.1016/j.echo.2011.02.012. PubMed: 21477990.
11. Saha SK, Camma J, Lip GY, De Caterina R, Savelieva I, Atar D et al. (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association. *Europace* 14: 1385–1413. doi:10.1093/europace/eus305. PubMed: 22923145.
12. Lane DA, Lip GY (2012) Use of the CHA<sub>2</sub>(DS)<sub>2</sub>-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. *Circulation* 126: 860–865. doi: 10.1161/CIRCULATIONAHA.111.060061. PubMed: 22891166.
13. Lang RM, Foster E, Pellikka PA, Picard MH et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography. *Journal Of The American Society of Echocardiography*: 1440–1463.
14. Gutman J, Wang YS, Wahr D, Schiller NB (1983) Normal left atrial function determined by 2-dimensional echocardiography. *Am J Cardiol* 51: 336–340. doi:10.1016/S0002-9149(83)80061-7. PubMed: 6823848.
15. Eshoo S, Ross DL, Thomas L (2009) Impact of Mild Hypertension on Left Atrial Size and Function. *Circ Cardiovascular Imaging* 2: 93–99. doi:10.1161/CIRCIMAGING.108.793190. PubMed: 19808574.
16. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr* 2: 358–367.
17. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK et al. (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *Eur J Echocardiogr J Working Group Echocardiogr Eur Soc Cardiol* 10: 165–193. doi: 10.1093/ejehocard/jen204. PubMed: 1927005319187853.
18. Lester SJ, Tajika J, Nishimura R, Oh JK, Khandheria BK, et al. (2008) Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. *J Am Coll Cardiol* 51: 679–689. doi: 10.1016/j.jacc.2007.09.061. PubMed: 18279730.
19. Jarmert C, Melcher A, Caidahl K, Persson H, Rydén L et al. (2008) Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes. *Eur J Heart Fail* 10: 1080–1087. doi: 10.1016/j.ejheart.2008.08.012. PubMed: 18838296.
20. Harrell F (2001) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. *J Am Stat Assoc* 98: 257–258.
21. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D et al. (2004) Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. *Circulation* 109: 363–368. doi: 10.1161/01.CIR.0000109495.02213.52. PubMed: 14732752.
22. Allessie M, Ausma J, Schotten U (2002) Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res* 54: 230–246. doi: 10.1016/S0008-6363(02)00258-4. PubMed: 12062329.
23. Jarmert C, Melcher A, Caidahl K, Persson H, Rydén L et al. (2008) Left atrial velocity vector imaging for the detection and quantification of left ventricular diastolic function in type 2 diabetes. *Eur J Heart Fail* 10: 1080–1087. doi: 10.1016/j.ejheart.2008.08.012. PubMed: 18838296.
24. Stroke Prevention in Atrial Fibrillation Investigators (1995) Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation. the Stroke Prevention in Atrial Fibrillation Study. *J Stroke Cerebrovasc Dis* 4: p147–157.
25. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E et al. (2006) Recommendations for chamber quantification. *Eur J Echocardiogr J Working Group Echocardiogr Eur Soc Cardiol* 7: 79–108. doi: 10.1016/S1525-2167(06)60292-8. PubMed: 16458610.
26. McManus DD, Xanthakis V, Sullivan LM, Zachariah J, Aragam J et al. (2010) Longitudinal tracking of left atrial diameter over the adult life course: Clinical correlates in the community. *Circulation* 121: 667–674. doi: 10.1161/CIRCULATIONAHA.109.885806. PubMed: 20100973.
27. Jurcut R, Pappas CJ, Masci PG, Herbots L, Szulik M et al. (2008) Detection of Regional Myocardial Dysfunction in Patients with Acute Myocardial Infarction Using Velocity Vector Imaging. *J Am Soc Echocardiogr* 21: 879–886. doi: 10.1016/j.echo.2008.02.002. PubMed: 18356019.
28. Dokainish H, Nguyen JS, Sengupta R, Pillai M, Alam M et al. (2010) Do additional echocardiographic variables increase the accuracy of E/e' for predicting left ventricular filling pressure in normal ejection fraction? An echocardiographic and invasive hemodynamic study. *J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr* 23: 156–161. doi: 10.1016/j.echo.2009.11.015.
29. Yan P, Sun B, Shi H, Zhu W, Zhou Q et al. (2012) Left atrial and right atrial deformation in patients with coronary artery disease: a velocity vector imaging-based study. *PLOS ONE* 7: e51204. doi: 10.1371/journal.pone.0051204. PubMed: 23349657.
30. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY (2012) The value of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS<sub>2</sub> score 0-1: a nationwide cohort study. *Thromb Haemost* 107: 1172–1179. doi: 10.1160/TH12-03-0175. PubMed: 22473219.
31. Guyatt GH, Akl EA, Crowther M, Schünemann HJ, Gutterman DD et al. (2012) Introduction to the Ninth Edition: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed; American College of Chest Physicians. (2012) Evidence-Based Clinical Practice Guidelines. *Chest* 141: 48S–52S. doi: 10.1378/chest.11-2286. PubMed: 22315255.
32. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M et al. (2000) Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. *Circulation* 101: 2612–2617. doi: 10.1161/01.CIR.101.22.2612. PubMed: 10840013.
33. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K et al. (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. *J Am Coll Cardiol* 41: 2197–2204. doi: 10.1016/S0735-1097(03)00464-9. PubMed: 12821247.